Anti-NAGAB/ NAGA/ D22S674 functional antibody
Anti-NAGAB/ NAGA/ D22S674 functional antibody for cell culture, ELISA & in-vivo assay
Go to NAGA/NAGA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0361-Ab-1/ GM-Tg-hg-SE0361-Ab-2 | Anti-Human NAGA monoclonal antibody | Human |
GM-Tg-rg-SE0361-Ab-1/ GM-Tg-rg-SE0361-Ab-2 | Anti-Rat NAGA monoclonal antibody | Rat |
GM-Tg-mg-SE0361-Ab-1/ GM-Tg-mg-SE0361-Ab-2 | Anti-Mouse NAGA monoclonal antibody | Mouse |
GM-Tg-cynog-SE0361-Ab-1/ GM-Tg-cynog-SE0361-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NAGA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0361-Ab-1/ GM-Tg-felg-SE0361-Ab-2 | Anti-Feline NAGA monoclonal antibody | Feline |
GM-Tg-cang-SE0361-Ab-1/ GM-Tg-cang-SE0361-Ab-2 | Anti-Canine NAGA monoclonal antibody | Canine |
GM-Tg-bovg-SE0361-Ab-1/ GM-Tg-bovg-SE0361-Ab-2 | Anti-Bovine NAGA monoclonal antibody | Bovine |
GM-Tg-equg-SE0361-Ab-1/ GM-Tg-equg-SE0361-Ab-2 | Anti-Equine NAGA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0361-Ab-1/ GM-Tg-hg-SE0361-Ab-2; GM-Tg-rg-SE0361-Ab-1/ GM-Tg-rg-SE0361-Ab-2; GM-Tg-mg-SE0361-Ab-1/ GM-Tg-mg-SE0361-Ab-2; GM-Tg-cynog-SE0361-Ab-1/ GM-Tg-cynog-SE0361-Ab-2; GM-Tg-felg-SE0361-Ab-1/ GM-Tg-felg-SE0361-Ab-2; GM-Tg-cang-SE0361-Ab-1/ GM-Tg-cang-SE0361-Ab-2; GM-Tg-bovg-SE0361-Ab-1/ GM-Tg-bovg-SE0361-Ab-2; GM-Tg-equg-SE0361-Ab-1/ GM-Tg-equg-SE0361-Ab-2 |
Products Name | Anti-NAGA monoclonal antibody |
Format | mab |
Target Name | NAGA |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-NAGA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0361-Ag-1 | Recombinant multi-species NAGAB/ NAGA/ D22S674 protein |
ORF Viral Vector | vGMLP001189 | human NAGA Lentivirus particle |
ORF Viral Vector | pGMLP001189 | human NAGA Lentivirus plasmid |
ORF Viral Vector | pGMLPm002093 | mouse Naga Lentivirus plasmid |
ORF Viral Vector | vGMLPm002093 | mouse Naga Lentivirus particle |
Target information
Target ID | GM-SE0361 |
Target Name | NAGA |
Gene ID | 4668,17939,315165,713068,481226,101083277,533357,100070793 |
Gene Symbol and Synonyms | D22S674,GALB,NAGA |
Uniprot Accession | P17050,Q66H12,Q58DH9 |
Uniprot Entry Name | NAGAB_HUMAN,NAGAB_RAT,NAGAB_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000198951 |
Target Classification | N/A |
The target: NAGA, gene name: NAGA, also named as D22S674, GALB. NAGA encodes the lysosomal enzyme alpha-N-acetylgalactosaminidase, which cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. Mutations in NAGA have been identified as the cause of Schindler disease types I and II (type II also known as Kanzaki disease). [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.